MIRA Pharmaceuticals' SKNY-1 Shows Promising Anxiety Reversal in Preclinical Trials

MIRA Pharmaceuticals recently revealed promising preclinical results for SKNY-1, their oral drug candidate designed to combat obesity and nicotine addiction. In tests involving zebrafish, a model organism for studying anxiety, SKNY-1 effectively mitigated anxiety induced by CB1 receptor activation. This sets SKNY-1 apart from previous CB1-targeting drugs, which were discontinued due to adverse central nervous system effects.

SKNY-1's potential extends beyond anxiety mitigation. The drug achieved up to 30% weight loss and reversed cravings in animal studies without significant emotional or behavioral side effects. These attributes make it a potentially powerful treatment in large markets underserved by current options.

The drug acts on the endocannabinoid system through various pathways, offering a unique mechanism that may limit cravings while maintaining emotional stability. MIRA aims to move forward with acquisition plans and initiate studies to prep SKNY-1 for human trials.